4-Methylpyridine-3-boronic acid pinacol ester
Product Information
Molecular Formula
C12H18BNO2
Molecular Weight
219.09
Description
4-Methylpyridine-3-boronic acid pinacol ester is a biomedical product used in the treatment of various diseases. It acts as a potent inhibitor for specific enzymes related to cancer and autoimmune disorders, making it an effective therapeutic option. Additionally, this compound plays a crucial role in drug discovery and development processes, aiding in the design and synthesis of novel pharmaceutical agents.
Synonyms
4-Methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine; 4-Methylpyridine-3-boronic acid pinacol ester; 4-methyl-3-(tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine; (4-METHYLPYRIDIN-3-YL)BORONIC ACID PINACOL ESTER; 4-Methylpyridine-3-boronic acid pinacol ester, 96%; Z1336745167; 2-(4-Methyl-3-pyridyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane; Pyridine, 4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-
IUPAC Name
4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine
SMILES
B1(OC(C(O1)(C)C)(C)C)C2=C(C=CN=C2)C
InChI
InChI=1S/C12H18BNO2/c1-9-6-7-14-8-10(9)13-15-11(2,3)12(4,5)16-13/h6-8H,1-5H3
InChI Key
GZYZXNXJTPRMKF-UHFFFAOYSA-N
Melting Point
103-107 °C
Purity
96%
Storage
−20°C
Computed Properties
Hydrogen Bond Donor Count
0
Hydrogen Bond Acceptor Count
3
Rotatable Bond Count
1
Exact Mass
219.1430590 g/mol
Monoisotopic Mass
219.1430590 g/mol
Topological Polar Surface Area
31.4Ų
Heavy Atom Count
16
Formal Charge
0
Complexity
252
Isotope Atom Count
0
Defined Atom Stereocenter Count
0
Undefined Atom Stereocenter Count
0
Defined Bond Stereocenter Count
0
Undefined Bond Stereocenter Count
0
Covalently-Bonded Unit Count
1
Compound Is Canonicalized
Yes
Patents
| Publication Number | Title | Priority Date |
|---|---|---|
| CN-113912595-A | Compound containing thiazole or thiadiazole structure and application thereof | 2021-10-12 |
| US-2022002299-A1 | Tricyclic pyridone compounds as jak2 v617f inhibitors | 2020-07-02 |
| WO-2022006456-A1 | Tricyclic pyridone compounds as jak2 v617f inhibitors | 2020-07-02 |
| WO-2021159993-A1 | Inhibitors of interleukin-1 receptor associated kinase (irak) /fms-like receptor tyrosine kinase (flt3), pharmaceutical products thereof, and methods thereof | 2020-02-14 |
| US-2021269434-A1 | Tricyclic compounds as inhibitors of kras | 2020-01-10 |
| WO-2021142252-A1 | Tricyclic compounds as inhibitors of kras | 2020-01-10 |
| WO-2021004535-A1 | Cinnolines as inhibitors of hpk 1 | 2019-07-11 |
| WO-2021004547-A1 | Heterocyclic compounds as inhibitors of hpk1 | 2019-07-11 |
| WO-2020177629-A1 | Spiro-substituted pyrimidine-fused cyclic compound, preparation method therefor and medical use thereof | 2019-03-01 |
| TW-202031644-A | Benzimidazole derivative | 2018-11-06 |
